Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-04-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
上海荣正投资咨询股份有限公司关于昆药集团股份有限公司2017年限制性股票激励计划首次授予部分第一期解除限售及回购注销部分限制性股票事项之独立财务顾问报告
Regulatory Filings
2019-04-24 Chinese
德恒昆明关于昆药集团回购注销部分限制性股票相关事项的法律意见
Regulatory Filings
2019-04-24 Chinese
独立董事关于昆药集团九届十次董事会相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from independent directors regarding the repurchase and cancellation of restricted stock under a 2017 stock incentive plan and the lifting of restrictions on certain shares. It discusses compliance with relevant regulations and the legality of the procedures, focusing on stock incentive plan matters. This is not a full financial report, earnings release, or management discussion. It is a formal opinion related to corporate governance and stock incentive plan implementation, which fits best under Board/Management Information (MANG) as it involves board-level decisions and opinions on management matters related to stock incentives.
2019-04-24 Chinese
德恒昆明关于昆药集团回购注销的法律意见
Regulatory Filings
2019-04-24 Chinese
上海荣正投资咨询股份有限公司关于昆药集团股份有限公司2017年限制性股票激励计划首次授予部分第一期解除限售及回购注销部分限制性股票事项之独立财务顾问报告
Regulatory Filings
2019-04-24 Chinese
九届十次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details decisions regarding the repurchase and cancellation of restricted stock under a 2017 stock incentive plan and the lifting of restrictions on certain shares. The document includes voting results and references to related announcements but does not contain financial statements or detailed financial performance data. It is clearly a Board/Management Information announcement about board decisions and internal company governance matters rather than a full report or financial disclosure.
2019-04-24 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.